Get started
Author

Karmele Mujika

Observed names: Eizmendi, Karmele Mujika, K. Mujika, K. Mujika Eizmendi, Karmele Mujika Eizmendi
Institution: Onkologikoa
OpenAlex ID: A5075856383
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study
2023 · Reinhard Dummer, Paola Queirolo, et al. · The Lancet Oncology · 60
The Circulating Transcriptome as a Source of Biomarkers for Melanoma
2019 · Carla Solé, Daniela Tramonti, et al. · Cancers · 45
PDF
RETRACTED: Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study
2022 · Reinhard Dummer, Paola Queirolo, et al. · The Lancet Oncology · 42
SEOM clinical guideline for the management of cutaneous melanoma (2020)
2021 · M. Majem, J. L. Manzano, et al. · Clinical & Translational Oncology · 30
Serum markers improve current prediction of metastasis development in early‐stage melanoma patients: a machine learning‐based study
2020 · Filippo Mancuso, Sergio Lage, et al. · Molecular Oncology · 29
PDF
Melanoma and immunotherapy bridge 2015
2016 · Vashisht G. Y. Nanda, Weiyi Peng, et al. · Journal of Translational Medicine · 22
PDF
A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma
2023 · Juanita Lopez, Julia Lai-Kwon, et al. · British Journal of Cancer · 15
PDF
BRAF V600E mutational load as a prognosis biomarker in malignant melanoma
2020 · Arrate Sevilla, M. Celia Morales, et al. · PLoS ONE · 13
PDF
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB–IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study
2026 · Reinhard Dummer, Jun Guo, et al. · The Lancet Oncology · 12
KEYNOTE-555 Cohort B: Efficacy, safety, and PK of pembrolizumab (pembro) 400 mg every 6 weeks (Q6W) as 1L therapy for advanced melanoma.
2021 · Conrad R. Jacobs, Bernardo Leon Rapoport, et al. · Journal of Clinical Oncology · 12
Adjuvant Therapy Versus Watch-and-Wait Post Surgery for Stage III Melanoma: A Multicountry Retrospective Chart Review
2019 · Peter Mohr, Felix Kiecker, et al. · Melanoma Management · 12
PDF
Dabrafenib plus trametinib for compassionate use in metastatic melanoma
2017 · Salvador Martín Algarra, Virtudes Soriano, et al. · Medicine · 10
Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study
2024 · Graham Cohen, Bernardo Rapoport, et al. · PLoS ONE · 7
A study on MSH2 and MLH1 mutations in hereditary nonpolyposis colorectal cancer families from the Basque Country, describing four new germline mutations
2009 · Cristina Martínez-Bouzas, Elena Beristain, et al. · Familial Cancer · 6
Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first‐line anti‐programmed death‐1 monotherapy: A real‐world multicentre observational cohort study
2023 · Sebastian Ochenduszko, Javier García Sanchez, et al. · Pigment Cell & Melanoma Research · 5
Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL)
2022 · Inés González-Barrallo, Victoria Eugenia Castellón Rubio, et al. · Melanoma Research · 5
Abstract CT557: Phase 1/2 study of quavonlimab (Qmab) + pembrolizumab (pembro) in patients (pts) with advanced melanoma that progressed on a PD-1/PD-L1 inhibitor
2022 · Sanjeev Deva, Jacek Mackiewicz, et al. · Cancer Research · 4
Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive melanoma with central nervous system (CNS) metastases (mets): Primary results from phase 2 Tricotel study.
2022 · Reinhard Dummer, Paola Queirolo, et al. · Journal of Clinical Oncology · 4
1118P Retrospective analysis of safety in elderly BRAF V600 mutation-positive advanced melanoma patients treated with dabrafenib (D) and trametinib (T) and correlation with non-elderly patients
2020 · A. García-Castaño, I. González-Barrallo, et al. · Annals of Oncology · 3
PDF
Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801
2025 · Enrique Espinosa, Miguel-Ángel Berciano-Guerrero, et al. · Clinical & Translational Oncology · 1
PDF
Relation between dabrafenib plus trametinib-induced pyrexia and age in BRAF V600-mutated metastatic melanoma patients: A post hoc analysis of the real-world ELDERLYMEL study
2025 · Inés González-Barrallo, Victoria Eugenia Castellón Rubio, et al. · Melanoma Research · 1
Real‐world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study
2026 · Miguel‐Ángel Berciano‐Guerrero, Elisabeth Pérez‐Ruiz, et al. · Cancer
New Endpoints And Outcomes Of Immunotherapy In Patients With Advanced Melanoma: Results From The Real-World Study GEM1801
2026 · E. Muñoz-Couselo, G. Crespo, et al. · EJC Skin Cancer
PDF
1061P Safety of cemiplimab for advanced cutaneous squamous cell carcinoma: The Spanish named patient programme
2021 · A. Garcia Castano, E. Muñoz Couselo, et al. · Annals of Oncology
A new clinical tool to predict outcome in early-stage melanoma patients
2019 · Filippo Mancuso, Sergio Lage, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Works count: 27
Citation count: 338
H-index: 11
I10-index: 12
Year
Topic
Type